X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Company intends to use the proceeds to continue pipeline development of its candidates including INM-755, advance manufacturing of cannabinoids and cannabinoid analog, support intellectual property development, commercial activities, and for general working capital purposes.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 13, 2022
Details:
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Baymedica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
In the peer-reviewed study, researchers analyzed the effects of rare INM-755 (cannabinol) THCV, CBC, cannabigerol (“CBG”) and cannabigerolic acid (“CBGA”) on the major endocannabinoid system elements in skin cells.
Lead Product(s): Cannabinol
Therapeutic Area: Genetic Disease Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
The Company intends to use the net proceeds from the offerings to continue pipeline development including INM-755 (cannabinol), advance commercial activities and for general working capital purposes.
Lead Product(s): Cannabinol
Therapeutic Area: Genetic Disease Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 06, 2022
Details:
The Company intends to use the net proceeds from the offerings to continue pipeline development including INM-755 having cannabinol, advance commercial activities and for general working capital purposes.
Lead Product(s): Cannabinol
Therapeutic Area: Genetic Disease Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 02, 2022
Details:
This patent covers the selective modification of naturally occurring cannabinoids to target specific properties for pharmaceutical development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of L’Aquila
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2022
Details:
Preclinical data demonstrate that INM-755 (cannabinol) cream may help relieve hallmark EB symptoms, such as inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
InMed Pharmaceuticals has entered into a non-binding letter of intent (the "LOI") to acquire BayMedica Inc. (“BayMedica”), a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: InMed Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 29, 2021
Details:
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 29, 2021
Details:
All four subtypes of inherited EB are eligible for this study in which InMed will evaluate the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and healing wounds over a 28-day period.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
Details:
InMed intends to use the net proceeds from the offering for working capital purposes which also includes development of their INM-755 program.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 16, 2021
Details:
The licensing agreement with EyeCRO grants InMed an exclusive, worldwide license to develop and commercialize prospective therapeutic formulations combining MiDROPS® with any and all cannabinoid molecules.
Lead Product(s): Cannabinol
Therapeutic Area: Ophthalmology Product Name: INM-088
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: InMed Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 03, 2020
Details:
InMed intends to use the net proceeds from the offering for funding preclinical and clinical development of its cannabinoid drug candidates INM-755 (dermatology) and INM-088 (ocular diseases), advancing its IntegraSynTM manufacturing platform, and for working capital purposes.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 16, 2020
Details:
INM-755 is being developed as a topical CBN-based cream to potentially treat Epidermolysis Bullosa as well as potentially other dermatological diseases.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
The 755-102-HV clinical trial is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Combination of CBN and elevated pressure, within the same time period, resulted in a high level of cell survival in a dose dependent fashion. CBN was superior to both CBD and THC under identical testing conditions.
Lead Product(s): Cannabinol
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
With INM-088, an eye drop formulation of CBN, the Company is exploring the treatment for glaucoma, either as a prospective stand-alone or an adjunct therapy, and in other ocular diseases.
Lead Product(s): Cannabinol
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
Study 755-101-HV is a randomized Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
755-102-HV will evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
With enrollment completed, treatment is expected to conclude towards the end of March and results are anticipated to be announced in the second half of calendar 2020.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
Details:
InMed Pharmaceuticals, revealed the rare cannabinoid cannabinol as the active pharmaceutical ingredient in its two product candidates under development: INM-755 for epidermolysis bullosa and INM-088.
Lead Product(s): Cannabinol
Therapeutic Area: Rare Diseases and Disorders Product Name: INM-755
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
